Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Boehringer In­gel­heim is build­ing on its col­lab­o­ra­tion with OSE Im­munother­a­peu­tics by in­ves­ti­gat­ing two clin­i­cal-stage on­col­o­gy pro­grams in car­dio-re­nal-meta­bol­ic dis­ease and adding a third pre­clin­i­cal can­cer

After cardiac surgery, women were particularly vulnerable to poor outcomes in the long run if the most common procedural complication had occurred, according to a